Abstract
Studying the safety of drugs used in pregnancy, especially psychotropics, is a complicated process with currently no ideal model for conducting studies. Because of the ethical issues surrounding pregnancy it is highly unlikely Randomized Controlled Trials (RCTs) will ever be conducted. Consequently, observational studies are used and all of the models have their limitations, such as small sample size, retrospective bias, inability to know exactly if the women took their medication in pregnancy, and other missing data. However, this does not mean that the data collected are not valuable and useful to provide evidence-based information. Psychopharmacology and pregnancy is a highly sensitive topic with healthcare providers, with the media being very interested and eager to report findings, especially if adverse effects are reported. Consequently, it is of great importance when evaluating these studies, to point out the limitations of each study and how it may affect the results. For best evidence, a combination of these different types of observational studies will assist women and their healthcare providers in making informed decisions as to whether or not to take a particular drug during pregnancy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol. 2009;201(6):579.
Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010–5.
Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87.
Conter V, Cortinovis I, Rogari P, Riva L. Weight growth in infants born to mothers who smoked during pregnancy. BMJ. 1995;310(6982):768.
Domar AD, Moragianni VA, Ryley DA, Urato AC. The risks of selective serotonin reuptake inhibitor use in infertile women: a review of the impact on fertility, pregnancy, neonatal health and beyond. Hum Reprod. 2013;28(1):160–71.
Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867–72.
Edwards DRV, Aldridge T, Baird DD, Funk MJ, Savitz DA, Hartmann KE. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol. 2012;120(1):113–22.
Einarson A. Antidepressants and pregnancy: complexities of producing evidence-based information. CMAJ. 2010;182(10):1017–8.
Einarson A, Koren G. First trimester exposure to paroxetine and prevalence of cardiac defects: meta‐analysis of the literature: unfortunately incomplete. Birth Defects Res A Clin Mol Teratol. 2010;88(7):588.
Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm. 1988;22(10):813–24.
Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158(10):1728–30.
Einarson TR, Lee C, Smith R, Manley J, Perstin J, Loniewska M, et al. Quality and content of abstracts in papers reporting about drug exposures during pregnancy. Birth Defects Res A Clin Mol Teratol. 2006;76(8):621–8.
Einarson A, Smart K, Vial T, Diav-Citrin O, Yates L, Stephens S, et al. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. J Clin Psychiatry. 2012a;73(11):1471.
Einarson TR, Kennedy D, Einarson A. Do findings differ across research design? The case of antidepressant use in pregnancy and malformations. J Popul Ther Clin Pharmacol. 2012b;19(2):e334–48.
Elstein AS. On the origins and development of evidence-based medicine and medical decision making. Inflamm Res. 2004;53(S2):S184–9.
Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, et al. Pregnancy outcome following gestational exposure to echinacea: a prospective controlled study. Arch Intern Med. 2000;160(20):3141.
Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163(6):493–501.
Grigoriadis S, Vonderporten EH, Mamisashvili L, Eady A, Tomlinson G, Dennis CL, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e309–20.
Källén BA, Otterblad OP. Use of oral decongestants during pregnancy and delivery outcome. Am J Obstet Gynecol. 2006;194(2):480–5.
Källén B, Nilsson E, Olausson PO. Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol. 2011;67(8):839–45.
Kazy Z, Puhó EH, Czeizel AE. Effect of doxycycline treatment during pregnancy for birth outcomes. Reprod Toxicol. 2007;24(3):279–80.
McBride WG. Letters to the editor: thalidomide and congenital abnormalities. Lancet. 1961;278(7216):1358.
Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ. 2001;322(7281):266–70.
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898–906.
Pochi PE, Ceilley RI, Coskey RJ, Drake LA, Jansen GT, Rodman OG, et al. Guidelines for prescribing isotretinoin (Accutane) in the treatment of female acne patients of childbearing potential. Acne Subgroup, Task Force on Standards of Care. J Am Acad Dermatol. 1988;19(5):920.
Reis M, Källén B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open. 2013;3(2):e002166.
Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005;193(6):2004–9.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.
Wogelius P, Nørgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006;17(6):701–4.
Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta‐analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88(3):159–70.
Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI, et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol. 2004;19(2):235–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Einarson, A. (2014). Critical Evaluation of the Literature: Understanding the Complexities of Observational Research. In: Galbally, M., Snellen, M., Lewis, A. (eds) Psychopharmacology and Pregnancy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54562-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-54562-7_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54561-0
Online ISBN: 978-3-642-54562-7
eBook Packages: MedicineMedicine (R0)